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An imipenem-resistant Bacteroides fragilis strain was isolated from the blood of
a 72-year-old male patient with a urinary bladder tumor in Osijek, Croatia. This strain
was also resistant to ampicillin, piperacillin/tazobactam, cefoxitin, clindamycin, tetra-
cycline, and harbored cﬁA, ermF, and tetQ genes where the high-level expression of the
cﬁA carbapenem-resistant gene was driven by an IS1187 element. Interestingly, despite
the carbapenem-resistant feature of the B. fragilis from blood, the patient relatively
easily recovered from the bacteremia. It was the ﬁrst characterized imipenem-resistant
B. fragilis isolate with its case report from Croatia, which conﬁrmed the appearance of
carbapenem-resistant B. fragilis strains, that continues worldwide with low incidence
and the molecular characteristics vary temporally and geographically.
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Introduction
Bacteroides fragilis is the most commonly isolated opportunistic anaerobic
pathogen, which is also a member of the normal microbiota. It comprizes 60%–
80% of the isolated anaerobic pathogens, but gives a Bacteroides count of only
0.5%–1% in the gut. The infections caused vary from mild to life-threatening
conditions, such as diarrhea, abdominal abscessi, other superﬁcial soft-tissue
infections, or sepsis. As a member of its parent genus, the Bacteroides, it is
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highly resistant to antibiotics regarding both the prevalence and the number of
resistance mechanisms. B. fragilis is often resistant to regular β-lactams
(penicillins and cephalosporins) (about 99%) and tetracyclines (about 70%). It
may be resistant (about 10%–30%) to cephamycins (cefoxitin), clindamycin, or
moxiﬂoxacin. The best available antibiotics are β-lactam/β-lactamase inhibitor
combinations, carbapenems, metronidazole, or tigecycline. Its carbapenem resis-
tance is mediated by a metallo-β-lactamase, which is coded by the cﬁA gene [1].
This gene is present to a signiﬁcant extent in the B. fragilis population, of which a
distinct subgroup of the species can be identiﬁed by molecular methods. To be
highly carbapenem-resistant, an insertion sequence (IS) element is necessary
whose role is to provide a strong promoter for expression [2]. As we mentioned,
the prevalence of true carbapenem-resistant B. fragilis strains is low, but such
strains might still pose a serious treatment problem, if it is unrecognized [3]. The
involvement of IS elements in driving the phenotypic expression of other
antibiotic-resistant genes [cepA – penicillin, cephalosprorin, cfxA – cephamycin,
ermF – clindamycin, and nim – metronidazole] different from cﬁA is well known
for clinical Bacteroides strains [1].
In this report, we describe a case and characterization of an imipenem-
resistant B. fragilis strain isolated at the Institute of Public Health for
Osijek-Baranja County, Osijek, Croatia. Resistance to carbapenems among
Bacteroides spp. isolates was previously reported in Croatia by Novak et al. [4],
but the mechanisms of resistance were not characterized or described.
Materials and Methods
The Bacteroides strains (n= 15) in this study were isolated from clinical
specimens at the Institute of Public Health for Osijek Baranja County, Osijek,
Croatia, they were identiﬁed and cultured by routine methods [5], and their
diagnostic antibiotic susceptibility measurements were performed by the ATB AN®
System (bioMerieux, France). For long-term storage of the strains, their brain–heart
infusion cultures containing 20% glycerol were stored at −70 °C. After sending the
strains to the Institute of Clinical Microbiology, University of Szeged, Szeged,
Hungary and ESCMID Study Group on Anaerobic Infections (ESGAI) cooperation,
their species identities and associated genetic division of B. fragiliswere analyzed by
MALDI-TOF MS (Microﬂex, Bruker Daltonics, Bremen, Germany) [6]. Antibiotic
susceptibility conﬁrmation of B. fragilis O4/13 (the only imipenem-resistant strain
belonging to genetic Division II) was performed by the E-test method, as described
by bioMeriux. Susceptibility/resistance categorization was carried out according to
the EUCAST (http://www.eucast.org/clinical_breakpoints/) recommendations and
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since they are not available for moxiﬂoxacin and tigecycline, we used the data
from Eitel et al. [7].
The presence of antibiotic-resistant genes (cepA, cfxA, cﬁA, nim, ermF,
bexA, tetQ, tetX, and tetX1) and their activation IS elements was detected as
described earlier [8]. In brief, DNA templates were prepared by the boiling method
and RT-PCR was carried out in 10 μl ﬁnal volumes using 5 μl of Brilliant II RT-
PCR master mix with SybrGREEN and ROX dyes (Agilent, Santa Clara, CA,
USA), 0.7 μM of primers, and 1 μl of DNA templates with the primers and cycling
conditions described earlier, using a StepOne RT-PCR instrument (LifeTechnol-
ogies). The harboring of the enterotoxin gene (bft) was detected in a similar way as
the antibiotic-resistant genes as described in [9]. The plasmid content was
examined using the Birnboim–Doly alkalic detergent lysis method [9, 10].
Results
In the period 2013–2016, antibiotic susceptibility testing using commercially
available microdilution test ATBAN® for 15 B. fragilis group strains was carried out
at the Institute of Public Health for Osijek-Baranja County and one, namely
B. fragilis O4/13, proved to be imipenem-resistant. These strains were sent to the
Institute of Clinical Microbiology, University of Szeged in an ESGAI cooperation.
Their species identiﬁcations were conﬁrmed byMALDI-TOFMS and this strain also
turned out to belong to Division II of B. fragilis by the MALDI-TOF MS project
analysis (the remaining ones belonged to Division I). The case for this isolate is
described as follows. The male patient (born in 1941) underwent an operation to
remove a urinary bladder tumor (Dg: Adenocarcinoma vesicae urinariae) in January
2013 when a nephrostomal catheter along with permanent urinary catheter was
inserted. In the following months, he regularly visited his urology specialist. During a
checkup in August, he complained of a pus discharge from his nephrostomal catheter
and was admitted to the infectious diseases ward at the University Hospital Osijek,
Osijek, Croatia for further treatment. On admission, he was afebrile, and his blood
pressure was 110/70 mmHg, and ECG without any abnormalities (sinus rhythm,
heart rate: 92 beats/min). The laboratory ﬁndings were as follows: 86.7 mg/L
C-reactive protein (CRP), 10.9× 109/L WBC, 2.37× 1012/L RBC, 62 g/L hemo-
globin, 0.189 hematocrit, 293× 109/L platelets, 25.5 mol/L urea, 425 μmol/L
creatinine, 136 mmol/L Na, 5.2 mmol/L K, 14 U/L aspartate aminotransferase
(glutamate oxaloacetate transaminase), 27 U/L alanine aminotransferase (glutamate
pyruvate transaminase), and 51 U/L gamma glutamyl transferase. From a urine
sample collected using the left nephrostomal catheter, an extended-spectrum
β-lactamase-producing Klebsiella pneumoniae was isolated. Since the patient was
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not allergic to antibiotics, along with replacement of the indwelling catheter therapy
with ertapenem 1× 1 g was introduced. On the fourth day of hospitalization, the
patient experienced a peak in elevated body temperature (38 °C), so blood was
collected for a blood culture set. From the inoculated anaerobic bottle, the B. fragilis
was isolated and the aerobic bottle remained sterile. The ertapenem therapy was
continued in spite of this. It is worth adding that the patient also had an anus praeter
placed following radical surgery due to a malignant growth in the rectum 5 years
earlier. After 7 days of ertapenem therapy and two transfusions (RBC concentrate,
blood group 0, Rh-positive), the patient’s health improved. At this point, his
laboratory ﬁndings were as follows: 27.5 mg/L CRP, 11.1× 109/L WBC, 3.12/L
RBC, 92 g/L hemoglobin, 0.277 hematocrit, 347× 109/L platelets, 19 mmol/L urea,
329 μmol/L creatinine, 144 mmol/L Na, 4.8 mmol/L K, and repeated culture of urine
sample remained sterile. After resolving the acute urinary tract infection (K. pneu-
moniae) by ertapenem and the bacteremia probably due to the blood transfusion, he
was transferred to the oncology department for continuing further treatment of
developed metastatic processes. The treatment with capecitabin and irinotecan was
continued and the patient was released and sent home with the recommendation of
regular oncology checkups.
The B. fragilis O4/13 strain was further characterized by microbiological and
molecular methods reported earlier. The data obtained by these methods are shown
in Table I. The strain was resistant to ampicillin, piperacillin/tazobactam, cefoxitin,
imipenem, clindamycin and tetracycline, intermediate-resistant to amoxicillin/
clavulanate and susceptible to metronidazole, moxiﬂoxacin, tigecycline, and chlor-
amphenicol. From these results, it was classed as a multidrug-resistant (MDR) isolate,
since it exhibited resistance to three classes of antibiotics (β-lactams, lincosamide, and
tetracycline). However, this distinction is not so clear-cut, since the penicillin/
cephalosporin, clindamycin, and tetracycline resistances are fairly frequent among
Bacteroides and Parabacteroides strains. We detected the cﬁA gene with an upstream,
activating IS element (IS1187) explaining the β-lactam resistances [11], an ermF gene
and the common tetQ gene that might have caused the tetracycline resistance. The
clindamycin resistance might have been caused by the ermF gene, but we did not ﬁnd
the IS4351 element in its upstream region (Table I). However, such instances are
known where the clindamycin resistance can be explained by the ermF gene without
the well-known IS4351 [8]. No enterotoxin (fragilysin), bft, gene was detected in the
strain and the only plasmid that was detected in it was a 4.1 kb cryptic plasmid.
Discussion
In this study, we described a carbapenem-resistant B. fragilis strain isolated
in Osijek, Croatia, with the description of its clinical case and additionally we also
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reported its microbiological and molecular biological characterizations. In this
concern, we can add that true/phenotypic carbapenem resistance is still very rare
among Bacteroides. However, there were numerous batch studies that reported
this kind of resistance to several strains in France, Japan, USA, Hungary, Kuwait,
all over Europe, Korea, Denmark, and Turkey [2, 12–17]. Several other studies
reported unique strains that were isolated separately [18, 19]. For these latter
strains, we also know the clinical backgrounds that were often critical to the
patients harboring them. Usually, their MDR phenotypes were the major obstacles
in treating the patients empirically [3]. Although the present strain isolated in
Osijek, Croatia, could be regarded as MDR, the patient fortunately recovered from
it with only a little help and the strain did not harbor any other signiﬁcant
resistance type except for some resistance to clindamycin and tetracycline.
Overall, its carbapenem-resistance mechanism is consistent with our knowledge,
cﬁA with an IS element (IS1187) upstream, and it also indicates the spread of
IS1187, but the high clindamycin resistance (MIC> 256 μg/ml, ermF without
IS4351) requires further investigation. The characterization of this imipenem-
resistant B. fragilis strain from Osijek, Croatia, has contributed to our knowledge
or at least it warns us about the occurrence, importance, and biological variability
of carbapenem-resistant B. fragilis isolates.
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